Oncology Clinical Trial Finder
Breast Cancer

Recruiting • Phase NA • Stage III, IV • HER2 negative • Post-Menopausal • Non-interventional

The following is imported from ClinicalTrials.gov:

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

65 participant

Actual study start date:

December 12, 2022

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • CellSearch Circulating Tumor Cells

Inclusion criteria
  • invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease

  • er+/her2- patients prior to starting 2nd line therapy or beyond or er/progesterone receptor (pr)/her2-negative (triple negative) patients prior to starting any line of therapy

  • measurable and/or non-measurable disease is allowed

  • male or female breast cancer is allowed

  • age > 18 years

  • willingness to provide mandatory blood specimens

  • willing to return to enrolling institution for follow up imaging at least once

Exclusion criteria
  • life expectancy of ≤ 6 months

  • inability to provide blood samples based on the judgment of the treating provider

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:


Estimated Enrollment:


Last Updated:


Site Contact

Karthik Giridhar


Mayo Clinic

Rochester, Minnesota, United States, 55905

Trial Contact

Karthik Giridhar


(507) 284-2511

Trial Sponsor

Menarini Silicon Biosystems, INC

Study Location (4)

Mayo Clinic

Rochester, Minnesota, United States

MCHS Eau Claire

Eau Claire, Wisconsin, United States

Mayo Clinic Health System Albert Lea

Albert Lea, Minnesota, United States

Mayo Clinic Health System Mankato

Mankato, Minnesota, United States


© 2024 Outcomes4Me Inc. All rights reserved.